British Journal of Cancer · 2002 · 137 citations · 17 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyMetastasisAngiogenesisAngiogenesis In CancerEndothelial ActivationHematogenous MetastasisMetastatic Disease TreatmentAngiogenesis In NeoplasmsAngiogenic ModulationAngiogenic ResponseEndothelial Cell PhysiologyEndothelial ProliferationTumor Angiogenesis Models
NAMI-A is a ruthenium-based compound with selective anti-metastasis activity in experimental models of solid tumours. We studied whether this activity was dependent on anti-angiogenic ability of NAMI-A. We thus investigated its in vitro effects on endothelial cell functions necessary for angiogenesis to develop, as well as its in vivo effects in the chick embryo chorioallantoic membrane model. Endothelial cell proliferation, chemotaxis, and secretion of the matrix-degrading enzyme metalloproteinase-2 were inhibited by NAMI-A in a dose-dependent manner, and without morphologic signs of cell apoptosis or necrosis. Lastly, NAMI-A displayed a dose-dependent in vivo anti-angiogenic activity in the chorioallantoic membrane model. These data suggest that the anti-angiogenic activity of NAMI-A can contribute to its anti-metastatic efficacy in mice bearing malignant solid tumours.
17
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Noel Weidner, Joseph P. Semple, William R. Welch et al. · New England Journal of Medicine · 1991 · 5.7K citations
Medicine, Cancer Biology, Oncology +15
Harold E. Van Wart, Henning Birkedal‐Hansen · Proceedings of the National Academy of Sciences · 1990 · 1.5K citations